Skip to main content
Journal of Clinical Oncology logoLink to Journal of Clinical Oncology
. 2018 Mar 10;36(8):833–834. doi: 10.1200/JCO.2018.77.9884

Errata

PMCID: PMC6161940  PMID: 31329710

The November 1, 2015, article by Turcotte, et al, entitled “Risk of Subsequent Neoplasms During the Fifth and Sixth Decades of Life in the Childhood Cancer Survivor Study Cohort” (J Clin Oncol 33: 3568-3575), was published with errors. The authors, upon re-analysis of the data, identified an error in the initial analysis, which led to reporting incorrect results. Calculations of standardized incidence ratios (SIRs) erroneously included survivors’ person-years prior to age 40 years, resulting in an overestimation of the expected number of subsequent malignant neoplasms, and thus, an underestimation of the SIRs reported for malignancies after age 40 years among survivors of childhood cancer. Changes from the original report are described below and are presented in the Data Supplement Table. Findings remain consistent with what was initially reported. Previously significant observations have not been reversed. The magnitude of the findings is increased with the corrected analysis. The changes do not affect the main conclusions of the study.

Abstract: All SIR and RR values and corresponding 95% CIs were modified.

Results: Within the sub-section heading “Risk of SMNs Among Survivors With a History of SN Before Age 40 Years” all SIR values and 95% CIs were modified.

Within the sub-section heading “Risk of SMNs Among Survivors Without a History of SN Before Age 40 Years” all SIR values and 95% CIs were modified.

Within the first paragraph of sub-section heading “Multivariable Analyses” all RR values and corresponding 95% CIs for SMNs were modified.

The third sentence of the second paragraph of the Discussion originally read as: “For the CCSS at age 40 or older, the SIR was 2.2 (95% CI, 1.9 to 2.5).”

It has been corrected to read as: “For the CCSS at age 40 years or older, the SIR was 4.4 (95% CI, 3.8 to 5).”

The sentence, “Of interest, and somewhat encouragement, male survivors who attained an age of 40 years or older, who were not exposed to therapeutic radiation, did not have an increased risk for SMN after the age of 40 regardless of their SN history before this age” in the third paragraph of the Discussion was removed to reflect the updated analysis results.

The last sentence of the third paragraph of the Discussion originally read as, “Of the chemotherapeutic exposures, only treatment with platinum agents was significantly associated with development of an SMN after 40 years of age.”

It has been corrected to read as: “Of the chemotherapeutic exposures, treatment with platinum agents and epipodophylloxins were significantly associated with development of an SMN after 40 years of age.”

Table A2: The expected number of SMNs, SIRs, 95% CIs, and EARs were modified for “All Survivors Age ≥ 40 Years” and “Cohort Members Treated With Previous Irradiation” columns.

Table A3: The expected number of SMNs, SIRs, 95% CIs, and EARs were modified for “Cohort Members Not Treated With Previous Irradiation” columns.

Table A4: The relative risk, 95% CI, and P values were modified. Epipodophyllotoxin was added to the table to reflect its inclusion in the multivariable model.

The online version has been corrected in departure from the print. The authors apologize for the errors.


Articles from Journal of Clinical Oncology are provided here courtesy of American Society of Clinical Oncology

RESOURCES